Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Fosmetpantotenate · RE-024

Small molecule · developed by Travere Therapeutics

Phase 3 Most advanced trial (none active)
TVTX Developer
1 Registered trials

What is Fosmetpantotenate?

Fosmetpantotenate (RE-024) is a drug studied in Pantothenate Kinase-Associated Neurodegeneration, a rare inherited neurological disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
RE-024
Drug type
Small molecule
Therapy area
Neurology
Developer
Travere Therapeutics, Inc. (TVTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
VA101M0K2F

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03041116 Phase 3 Pantothenate Kinase-Associated Neurodegeneration Terminated TVTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pantothenate Kinase-Associated Neurodegeneration

More from Travere Therapeutics

Follow TVTX, the company behind Fosmetpantotenate

See TVTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TVTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.